Търсене на изпитвания

AI · Diabetes

Намерени 238 изпитвания за "Diabetes" Стр. 10 от 12

Предстои набиране Фаза 1

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

Diabetes Mellitus

A Study to Evaluate the Safety and Pharmacokinetics of AD-123 Compared to Coadministration of AD-1231 and AD-1232

Начало: 01.04.2026 Край: 01.05.2026 Възраст: от 19 г.

South Korea Addpharma Inc. NCT07538466

Предстои набиране

Does Pre-operative Gastric Ultrasound Influence Anaesthetic Decision-Making in Chronic Pain Patients? A Prospective Observational Cohort.

Gastric Ultrasound Gastric Ultrasound in Chronic Opioid Use (≥2 Weeks) Gastric Ultrasound in Poorly Controlled Acute-on-chronic Pain Gastric Ultrasound in Acute Opioid Administration Within 24 Hours Prior to the Procedure +3

Gastric POCUS has been validated and shown to be an accurate diagnostic tool in both healthy individuals and medically complex patient populations. Regional anaesthesiologists and pain management physicians frequently provide sedation or anaesthetic care for medically complex patients who fall outside the limited applicability of existing fasting guidelines, including patients with chronic pain, poor acute-on-chronic pain control, and those receiving acute or chronic opioid therapy. These patients are at risk of delayed gastric emptying and may therefore benefit from additional pre-procedural assessment using gastric ultrasound prior to elective interventions

Начало: 01.04.2026 Край: 01.08.2027 Възраст: от 18 г.

United Arab Emirates Danat Al Emarat Hospital NCT07537582

Предстои набиране Фаза 1

A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult Volunteers

Obesity & Overweight Type 2 Diabetes

Phase 1 Safety and Relative Bioavailability Study of DWRX5003 in Healthy Adults

Начало: 30.03.2026 Край: 30.08.2026 Възраст: 19–64 г.

South Korea Daewoong Pharmaceutical Co. LTD. NCT07539415

Активно (без набиране) Фаза 1

An Immunotherapy Vaccine (PIpepTolDC) for the Treatment of Patients With Type 1 Diabetes

Type 1 Diabetes Mellitus

This phase I trial investigates the side effects of PIpepTolDC vaccine in treating patients with type 1 diabetes who use insulin and don't have any other diabetes-related health complications. Type 1 diabetes is an autoimmune disease. This means that the immune system, which usually protects against foreign invaders like bacteria and viruses, attacks the body's insulin-producing betacells in the pancreas (autoimmune response). Overtime, the beta cells are destroyed by the immune system. To stay alive, people with type 1 diabetes must use insulin. PIpepTolDC vaccine is a type of immunotherapy (a treatment that uses a person's own immune system) that works like an allergy shot. The vaccine is made using one's own immune cells (dendritic cells) and a beta cell protein. The vaccine may teach the immune system to stop attacking the beta cells, which may help the beta cells recover and make enough insulin to control blood sugar levels. The vaccine may also help reduce future type 1 diabetes related complications.

Начало: 16.06.2022 Край: 15.12.2026 Възраст: 18–45 г.

United States City of Hope Medical Center NCT04590872

Активно (без набиране) Фаза 3

A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes

Obesity Overweight Type 2 Diabetes

The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes. Participants will be screened for about 4 weeks, after which they will enroll into either J2A-MC-GZP1, NCT06972459 (do not have type 2 diabetes) or J2A-MC-GZP2, NCT06972472 (have type 2 diabetes).

Начало: 15.05.2025 Край: 01.08.2027 Възраст: от 18 г.

Argentina, China, Czechia +4 Eli Lilly and Company NCT06993792

Активно (без набиране)

Evaluation of Pharmacist Intervention for Individuals With Uncontrolled Type 2 Diabetes

Diabetes Type 2

Type 2 diabetes is a chronic disease that can lead to a number of complications if uncontrolled and there is a projected increase of 33% patients living with diabetes over the next 10 years. There can be improvements to modifiable risk factors such as diet and exercise, in addition to medications. Treatment often involves a multidisciplinary approach with a physician, endocrinologist, dietitian, pharmacist and other support health professionals as required. This study will evaluate the effects of the pharmacists (or pharmD interns) intervention, looking at changes to the patients HbA1C, which is a measure of the patients blood glucose control over the previous 3 months as well as the patients understanding and comfort with managing their own diabetes via participant survey.

Начало: 04.07.2022 Край: 01.12.2026 Възраст: от 18 г.

Canada University of Manitoba NCT05442840

Активно (без набиране)

The REST Study for CGM Use in Older Adults With Insulin-treated Diabetes

Diabetes Mellitus

To assess the efficacy of the REST model in facilitating adoption and sustained use of CGM, in older adults with Type 1 diabetes (T1D) or Type 2 Diabetes (T2D) on complex insulin regimens. To examine barriers and enablers for the implementation feasibility of the REST intervention model using a mixed-methods approach. To assess the impact of REST model on economic factors and quality of life measures. The goal of this study is to facilitate the adoption of continuous glucose monitoring (CGM) in older adults (≥65 years) with diabetes mellitus (DM) on complex insulin regimens, and additionally, to build a framework for sustained CGM use over time using a novel patient-centered model - the REST model.

Начало: 20.04.2022 Край: 01.05.2026 Възраст: от 65 г.

United States Joslin Diabetes Center NCT05337826

Активно (без набиране) Фаза 3

I4V-MC-JAJJ: A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Baricitinib to Delay Stage 3 Type 1 Diabetes in At-risk Participants Aged ≥1 to

Diabetes Mellitus Type 1

Trial status: Authorised Time from Baseline to Diagnosis of Stage 3 Type 1 Diabetes [Time Frame: Baseline up to approximately 5 years]

Начало: 23.12.2025 Възраст: 18–64 г.

Belgium, Finland, France +8 Eli Lilly & Co. 2025-521797-34-00

Активно (без набиране) Фаза 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Overweight Obesity Type 2 Diabetes

This study will look at how much cagrilintide helps people with overweight or obesity and type 2 diabetes lower their body weight. Cagrilintide is a new investigational medicine. Doctors may not yet prescribe cagrilintide. Participant will either get cagrilintide or placebo. Which treatment participant get is decided by chance. Participants are two times more likely to get cagrilintide than placebo. Like all medicines, the study medicine may have side effects. For each participant, the study will last for about 1 year and 6 months.

Начало: 05.11.2025 Край: 30.06.2027 Възраст: от 18 г.

Argentina, Canada, Croatia +8 Novo Nordisk A/S NCT07220759

Активно (без набиране) Фаза 1

Effect of Rosmarinus Officinalis Extract on Oxidative Stress and Inflammatory Biomarkers in Patients With Type 2 Diabetes(T2DM)

Type 2 Diabetes Mellitus (T2DM) Oxidative Stress Inflammation Chronic

This study will evaluate the effects of Rosmarinus officinalis (rosemary) extract on oxidative stress and inflammation in patients with type 2 diabetes. Participants will be randomly assigned to receive either rosemary extract or a placebo for 12 weeks. The study aims to determine whether rosemary extract can improve health markers related to oxidative stress, inflammation, and metabolic function.

Начало: 20.09.2025 Край: 17.08.2026 Възраст: от 18 г.

Mexico Universidad Autonoma de Zacatecas NCT07541729

Активно (без набиране)

Evaluating Glucose Control Using a Next Generation Automated Insulin Delivery Algorithm in Adults With Type 2 Diabetes

Diabetes Mellitus

The purpose of the study is to assess the safety and efficacy of a next generation automated insulin delivery algorithm in adults with type 2 diabetes aged 16-70 years old

Начало: 01.07.2025 Край: 01.05.2026 Възраст: 16–70 г. Лечение

New Zealand Insulet Corporation NCT07039981

Активно (без набиране) Фаза 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity Overweight Type 2 Diabetes

The main purpose of this study is to see how orforglipron, compared with placebo, helps improve glycemic control in participants with obesity or with overweight and type 2 diabetes. This trial is part of the master protocol study J2A-MC-GZPO (NCT06993792). Participation in the study will last about 18 months.

Начало: 19.05.2025 Край: 01.08.2027 Възраст: от 18 г.

Argentina, China, Czechia +4 Eli Lilly and Company NCT06972472

Активно (без набиране) Фаза 2

Treatment of Type 1 Diabetes With Anti-OX40L Bispecific With Anti-TNF Activity In a Single Nanobody® Molecule

Type 1 Diabetes Mellitus

This is a randomized, placebo-controlled, parallel group, multicenter, double-blind Phase 2a, 2-arm study. The goal of this Phase 2a study is to assess safety and efficacy of brivekimig in comparison to placebo to preserve β-cell function in participants with recently diagnosed Stage 3 type 1 diabetes (T1D) on insulin therapy. The study design comprises 2 parts: in Part A adult participants (18 to 35 years of age at screening) and in Part B adolescent and young adult participants (age range 12 to 21 years) will be randomized into brivekimig and placebo groups. Approximately 84 participants will be included with randomization ratio 3:1 (active:placebo). The study includes a screening period (3 to 5 weeks), a double-blind treatment period of 52 weeks and a safety follow-up of 26 weeks.

Начало: 28.02.2025 Край: 29.04.2027 Възраст: 12–35 г. Лечение

Argentina, Australia, Brazil +5 Sanofi NCT06812988

Активно (без набиране) Фаза 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese Type 2 Diabetes Mellitus (T2DM)

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group dose-finding study to evaluate the efficacy and safety of enicepatide at low, middle, and high doses in participants who are overweight or obese with Type 2 diabetes mellitus (T2DM).

Начало: 21.11.2024 Край: 24.09.2026 Възраст: 18–75 г. Лечение

Argentina, Canada, Mexico +3 Carmot Therapeutics, Inc. NCT06628362

Активно (без набиране) Фаза 3

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both

Diabetes Mellitus, Type 2

This study will look at how much CagriSema lowers blood sugar and body weight in people with type 2 diabetes. CagriSema is a new investigational medicine. Doctors cannot yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide. Doctors can prescribe tirzepatide in some countries. Participants will either receive CagriSema or tirzepatide. Which treatment the participant will receive is decided by chance. For each participant, the study will last for up to 1 year and 4 months.

Начало: 05.11.2024 Край: 14.07.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +11 Novo Nordisk A/S NCT06534411

Активно (без набиране)

At-Home Exercise Study for Veterans With Healed Diabetic Foot Ulcers

Diabetic Foot Ulcer

Foot ulcers and amputations are a common and feared complication for people with diabetes. People with a diabetic foot ulcer have a higher risk of dying within five years than people with diabetes without an ulcer. At least one in four people with a new diabetic foot ulcer will die within five years, largely due to cardiovascular causes. The reasons for this increased mortality involve decreased mobility. People with a recently healed diabetic foot ulcer are considered "in remission" as opposed to "cured" because the underlying medical problems which led to their ulcer are still present. Once in remission, the current standard of care is to slowly increase ambulation. The problem is that people rarely return to the recommended level of mobility. The ability to safely maintain mobility with aging is critical. This pilot study is a small clinical trial to test the feasibility and acceptability of a home-based exercise regimen. The investigators will also assess if this home-based exercise regimen can increase mobility and function without increasing diabetic foot ulcer recurrence by improving lower extremity strength, lower extremity tissue perfusion and glycemic control.

Начало: 01.10.2024 Край: 31.03.2027 Възраст: от 50 г.

United States VA Office of Research and Development NCT06312579

Активно (без набиране) Фаза 2

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

Diabetes Mellitus, Type 1 Autoimmune Diseases Prevention

A 2-arm randomized Phase II Open Label Study to evaluate the safety and feasibility of intralymphatic administration of Diamyd® (Diamyd) also known as retogatein in individuals at risk of Type 1 diabetes carrying the HLA DR3-DQ2 haplotype.

Начало: 09.07.2024 Край: 31.03.2028 Възраст: 8–18 г.

Sweden Diamyd Medical AB NCT05683990

Активно (без набиране) Фаза 2

Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Diabetes Mellitus, Type 1

A multi-center, placebo-controlled, double blind, 1:1:1 randomized control clinical trial testing two different JAK Inhibitors abrocitnib, ritlecitinib, and placebo in subjects with recent onset Stage 3 Type 1 Diabetes within 100 days of diagnosis.

Начало: 19.10.2023 Край: 30.06.2027 Възраст: 12–35 г. Лечение

Australia, Canada, United States National Institute of Diabetes and Digestive and Kidney NCT05743244

Активно (без набиране) Фаза 3

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight

Type 2 Diabetes Obesity Overweight Obstructive Sleep Apnea

The purpose of this study is to is to evaluate the efficacy and safety of retatrutide in participants with type 2 diabetes in participants who have obesity or overweight (J1I-MC-GZBK master protocol) including a subset of participants who have obstructive sleep apnea (OSA) (J1I-MC-GSA2). The study will last about 89 weeks and will include up to 24 visits.

Начало: 11.07.2023 Край: 01.05.2026 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +5 Eli Lilly and Company NCT05929079

Активно (без набиране)

Effectiveness of a Combined mHealth-CBT Psychological Intervention to Improve Psychological Well-Being in Young Patients With T1D

Diabetes Mellitus, Type 1

Type 1 diabetes (T1D) can lead to psychological adjustments that impact the acceptance and management of this health condition, as well as the overall quality of life of patients, especially among the young. Therefore, there is a need for psychological interventions aimed at enhancing the psychological well-being of children and adolescents with T1D. The goal of this non-randomized controlled trial is to evaluate whether a combined intervention comprising mHealth (using an app) and face-to-face psychological sessions based on Barlow's protocol and cognitive-behavioral therapy techniques (CBT) is effective in enhancing psychological well-being in children and adolescents with T1D. The main hypotheses are: * H1: The primary results expected to be obtained are a significant increase in psychological well-being, which means a decreased diabetes distress (DDS) (H1a) an increased subjective well-being (PANAS) (H1b) and a better self-efficacy for managing their emotions (RESE) (H1c). * H2: As secondary outcomes, it is also expected that the combined mHealth-CBT intervention would increase the level of positivity (P-Scale) (H2a), the self-esteem (RSES) (H2b) and the satisfaction with life (SWLS) (H2c).

Начало: 11.02.2023 Край: 01.09.2026 Възраст: 6–18 г.

Spain Maimónides Biomedical Research Institute of Córdoba NCT06450730

1 … 8 9 10 11 12